Enumerate cause of opportunities mycosis
| Predisposing Condition | Associated Fungi |
|---|---|
| HIV/AIDS (CD4+ <200 cells/µL) | Candida spp., Cryptococcus neoformans, Pneumocystis jirovecii, Aspergillus spp., Talaromyces marneffei |
| Organ transplantation (on immunosuppressants) | Candida, Aspergillus, Cryptococcus, Pneumocystis jirovecii, Mucorales |
| Corticosteroid therapy (long-term/high-dose) | Aspergillus spp., Candida, Mucorales |
| Immunosuppressive therapy (e.g., calcineurin inhibitors, TNF-alpha blockers) | Aspergillus, Candida |
| Congenital T-cell deficiencies (DiGeorge, SCID) | Candida, Pneumocystis |
| Predisposing Condition | Associated Fungi |
|---|---|
| Hematologic malignancies (leukemia, lymphoma) | Aspergillus spp. (most important), Candida, Mucorales, Fusarium |
| Chemotherapy-induced neutropenia | Aspergillus fumigatus (key risk - angioinvasive disease), Candida |
| Hematopoietic stem cell transplantation (HSCT) | Aspergillus (prolonged neutropenia, GVHD), Candida |
| Aplastic anemia | Aspergillus, Candida |
| Chronic granulomatous disease (CGD) | Aspergillus spp. |
| Predisposing Condition | Associated Fungi |
|---|---|
| Broad-spectrum antibiotic use | Candida albicans (endogenous overgrowth) |
| Indwelling vascular catheters / prosthetic devices | Candida spp. (candidemia) |
| Total parenteral nutrition (TPN) | Candida |
| Surgery / burns | Candida, Aspergillus |
| Premature neonates (immature barriers) | Candida |
| Predisposing Condition | Associated Fungi |
|---|---|
| Diabetes mellitus (especially ketoacidosis) | Mucorales (Rhizopus, Mucor, Lichtheimia) - rhinocerebral mucormycosis is classic |
| Iron overload / deferoxamine therapy | Mucorales (Rhizopus) - deferoxamine acts as siderophore for fungi |
| Renal failure / uremia | Candida, Mucorales |
| Malnutrition | Candida, Pneumocystis jirovecii |
| Predisposing Condition | Associated Fungi |
|---|---|
| COPD / structural lung disease | Aspergillus (chronic pulmonary aspergillosis, ABPA) |
| Influenza or COVID-19 (ICU patients) | Aspergillus spp. (COVID-19-associated pulmonary aspergillosis - CAPA) |
| Liver failure / cirrhosis | Candida, Aspergillus, Cryptococcus |
| Extremes of age (neonates, elderly) | Candida |
| Hyper-IgE syndrome / CMC | Candida (chronic mucocutaneous candidiasis) |
| Fungus | Primary Host Defect |
|---|---|
| Candida spp. | Disrupted mucosal barriers, antibiotics, T-cell defects, catheters |
| Aspergillus spp. | Neutropenia (most critical), corticosteroids, lung transplant |
| Cryptococcus neoformans | T-cell defects (HIV/AIDS, transplant) |
| Pneumocystis jirovecii | T-cell defects (CD4+ <200 in HIV, steroids) |
| Mucorales (Rhizopus, Mucor) | Diabetes/ketoacidosis, neutropenia, deferoxamine use, iron overload |
| Fusarium spp. | Profound neutropenia, HSCT |
| Talaromyces marneffei | HIV/AIDS (Southeast Asia) |
| Trichosporon spp. | Neutropenia, HSCT |
| Scedosporium spp. | Transplant, near-drowning, chronic lung disease |